Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

How I Treat In Brief

How I Treat In Brief: Primary Mediastinal B-Cell Lymphoma

Recently, Lisa Giulino-Roth, MD, from Weill Cornell Medical College in New York, discussed the management of primary mediastinal B-cell lymphoma, a rare subtype of...

With PET-Guided Treatment, Can Radiation Be Eliminated in Early-Stage HL?

Combined modality treatment (CMT) consisting of chemotherapy and small-field radiotherapy has long been considered the standard of care for patients with early-stage, favorable Hodgkin...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

Certain Non-Hodgkin Lymphoma Subtypes Carry Higher Risk of Infection-Related Solid Tumor Cancers

Various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), carry a risk for second infection-related solid...
On location

Allogeneic or Autologous Transplant for Peripheral T Cell Lymphoma?

In a final analysis from the Autologous or Allogeneic Transplantation in T-Cell Lymphoma (AATT) trial, researchers found no differences in survival outcomes between consolidation...

Textured Breast Implants Recalled by FDA Over Cancer Risk

The U.S. Food and Drug Administration (FDA) has requested that pharmaceutical company Allergan recall its BIOCELL textured breast implants due to a risk of...
WIB_icon

Short, Aggressive Antibiotic Therapy Inhibits Lymphocyte Proliferation in CTCL

According to a study published in Blood, patients with advanced-stage cutaneous T cell lymphoma (CTCL) a short, yet aggressive, antibiotic regimen inhibited disease activity...

Polatuzumab Vedotin-piiq Receives FDA Approval for DLBCL

The FDA has approved the CD79b-directed antibody drug conjugate polatuzumab vedotin-piiq, in combination with bendamustine and rituximab (BR), to treat adults with relapsed or...
On location

Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas

In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.